People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...

The Centers for Medicare & Medicaid Services (CMS) said Friday that it had selected another 15 drugs for its second round of ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Metformin, an oral medication used to treat type 2 diabetes, is often prescribed off-label for weight loss. It helps to ...